Enhanced reactivity to malondialdehyde-modified proteins by systemic lupus erythematosus autoantibodies

Scandinavian Journal of Rheumatology

Volumn 39, Issue 3, 2010, Pages 247-253

  Ben Mansour, R ^a,f   Lassoued, S ^a   Elgaied, A ^a   Haddouk, S ^b   Marzouk, S ^c   Bahloul, Z ^c   Masmoudi, H ^b   Attia, H ^a   Aifa M S ^d   Fakhfakh, F ^e  

^a Université de Sfax   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

^c Hospital Hedi Chaker   (Tunisia)

^d CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^e UNIVERSITY OF SFAX   (Tunisia)

^f NONE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CATALASE; CELL PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MALONALDEHYDE; PEPTIDE DERIVATIVE; SUPEROXIDE DISMUTASE; THIOL GROUP;

ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANALYSIS OF VARIANCE; AUTOANTIBODIES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALONDIALDEHYDE; PROTEINS; SUPEROXIDE DISMUTASE;

EID: 77951840701     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903362511     Document Type: Article

References (63)

1. Sheikh Z, Ahmad R, Sheikh N, Ali R. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies Autoimmunity 2007; 40: 512-20. (Pubitemid 351233172)
2. Perl A. Pathogenesis and spectrum of autoimmunity. In: Perl A, editor. Autoimmunity, methods and protocols. Totowa, NJ: Humana Press, 2004: 1-8.
3. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 2003; 131: 398-404. (Pubitemid 36324129)
4. Mok CC, Ho LY, Cheung MY, Yu KL, To CH. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009; 38: 121-7.
5. Scofield RH, Kurien BT, Granick S, McClain MJ, Pye Q, James JA, et al.. Modification of lupus-associated 60-kDa Ro protein with the lipid oxidation product 4-hydroxy-2-nonenal increases antigenicity and facilitates epitopes spreading. Free Radic Biol Med 2005; 38: 719-28. (Pubitemid 40249742)
6. Levinson SS. Humoral mechanisms in autoimmune disease. J Clin Immunoassay 1994; 17: 72-84. (Pubitemid 2126958)
7. Lundberg I, Hedfors EJ. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991; 18: 1511-19.
8. Fritzler MJ, Ali R, Tan EM. Antibodies from patients with mixed connective tissue disease react with heterogeneous nuclear ribonucleoprotein or ribonucleic acid (hnRNP/RNA) of the nuclear matrix. J Immunol 1984; 132: 1216-22. (Pubitemid 14154540)
9. Mannik M, Nardella FA. IgG rheumatoid factors and selfassociation of these antibodies. Clin Rheum Dis 1985; 11: 551-72. (Pubitemid 16238187)
10. Cvetkovic JT, Wallberg-Jonsson, Ahmed ES, Rantapaa-Dahlqvist S, Lefvert AK. Increased levels of autoantibodies against copper-oxidised low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 2002; 41: 988-95.
11. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
12. Amara A, Constans J, Chaugier C, Sebban A, Dubourg L, Peuchant E, et al.. Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol 1995; 101: 233-8.
13. Ara J, Ali R. Polynucleoside specificity of anti-reactive oxygen species (ROS) DNA antibodies. Clin Exp Immunol 1993; 94: 134-9. (Pubitemid 23308378)
14. Bashir S. Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993; 52: 659-66.
15. Fenkel K, Karkoszka J, Kim E, Taioli E. Recognition of oxidized DNA bases by sera of patients with inflammatory diseases. Free Radic Biol Med 1993; 14: 483-94. (Pubitemid 23124527)
16. Vuolteenaho K, Moilanen T, Knowles RG, Moilanen E. The role of nitric oxide in osteoarthritis. Scand J Rheumatol 2007; 36: 247-58.
17. Lunec J, Herbert K, Blount S, Griffiths H, Emery P. 8- Hydroxydeoxyguanosine. A marker of oxidative DNA damage in systemic lupus erythematosus. FEBS Lett 1994; 348: 131-8. (Pubitemid 24227436)
18. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84. (Pubitemid 44566469)
19. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Met Rev 2000; 32: 307-26. (Pubitemid 32001909)
20. Toyoda K, Nagae R, Akagawa M, Ishino K, Shibata T, Ito S, et al. Protein-bound 4-hydroxy-2-nonenal: an endogenous triggering antigen of anti-DNA response. J Biol Chem 2007; 282: 25769-78. (Pubitemid 47372786)
21. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 2000; 28: 1685-96. (Pubitemid 30628655)
22. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003; 42: 318-43.
23. Haberland ME, Olch C, Folgeman AM. Role of lysine in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. J Biol Chem 1984; 259: 11305-11. (Pubitemid 14007783)
24. Steinbrecher P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-8.
25. Arutyunova EI, Danshina PV, Domnina LV, Pleten AP, Muronetz VI. Oxidation of glyceraldehyde-3-phosphate dehydrogenase enhances its binding to nucleic acids. Biochem Biophys Res Commun 2003; 307: 547-52.
26. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18: 815-21.
27. Griffiths HR. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun Rev 2008; 7: 544-9.
28. Salonen J, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al.. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-7.
29. Ben Mansour R, Lassoued S, Gargouri B, El Gaïd A, Attia H, Fakhfakh F. Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 2008; 37: 103-8. (Pubitemid 351536076)
30. Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Martínez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol. 2006; 144: 217-22.
31. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, et al.. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892-9. (Pubitemid 24372183)
32. Kurien BT, Scofield RH. Free radical mediated peroxidative damage in systemic lupus erythematosus. Life Sci 2003; 73: 1655-66. (Pubitemid 36869006)
33. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 2002; 40: 684-8. (Pubitemid 34982477)
34. Kurien BT, Scofield RH. Lipid peroxidation in systemic lupus erythematosus. Indian J Exp Biol 2006; 44: 349-56.
35. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128. (Pubitemid 121003917)
36. Morgan PE, Sturgess AD, Davies MJ. Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radic Res 2008; 18: 1-11.
37. Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 2008; 567-73.
38. Morgan PE, Sturgess AD, Hennessy A, Davies MJ. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic Res 2007; 12: 1301-12. (Pubitemid 350302186)
39. Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2069-79. (Pubitemid 41001420)
40. Lorber A, Pearson CM, Meredith WL, Gantz-Mandell LE. Serum sulfhydryl determinations and significance in connective tissue diseases. Ann Intern Med 1964; 61: 423-34.
41. Lorber A, Bovy RA, Chang CC. Sulfhydryl deficiency in connective tissue disorders: correlation with disease activity and protein alterations. Metabolism 1971; 20: 446-55.
42. Quinlan GJ, Evans TW, Gutteridge JM. Oxidative damage to plasma proteins in adult respiratory distress syndrome. Free Radic Res 1994; 20: 289-98. (Pubitemid 2094933)
43. Kadota K, Yui Y, Hattori R, Murohara Y, Kawai C. Decreased sulfhydryl groups of serum albumin in coronary artery disease. Jpn Circ J 1991; 55: 937-41.
44. Rasheed Z, Ali R. Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci 2006; 79: 2320-8. (Pubitemid 44666070)
45. Beal, MF. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002; 32: 797-803. (Pubitemid 34439250)
46. Martín-Gallán P, Carrascosa A, Gussinyé M, Domínguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-74. (Pubitemid 36638716)
47. Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic Biol Med 2006 41: 549-56. (Pubitemid 44080517)
48. Pacifici RE, Kono Y, Davies KJ. Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J Biol Chem 1993; 268: 15405-11. (Pubitemid 23222029)
49. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, et al.. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002; 46: 2686-94. (Pubitemid 36118933)
50. Youinou P. New target antigens for antiendothelial cell antibodies. Immunobiology 2005; 210: 789-97. (Pubitemid 41683864)
51. Chan TM, Frampton G, Staines NA, Hobby P, Perry JS, Cameron JS. Different mechanisms by which anti-DNA MoAbs bind to human endothelial cells and glomerular mesangial cells. Clin Exp Immunol 1992; 88: 68-74.
52. Del Papa N, Conforti G, Gambini D, La Rosa L, Tincani A, D'Cruz D, et al.. Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopathol 1994; 70: 211-16. (Pubitemid 24086595)
53. Morrow J, Nelson L, Watts R, Isenberg D. Autoimmune rheumatic disease. Oxford: Oxford University Press, 1999.
54. De Mendonca Neto EC, Kumar A, Shadick NA, Michon AM, Matsudaira P, Eaton RB, et al.. Antibodies to T-and L-isoforms of the cytoskelet al. protein, fimbrin, in patients with systemic lupus erythematosus. J Clin Invest 1992; 90: 1037-42.
55. Robbins ML, Kornguth SE, Bell CL, Kalinke T, England D, Turski P, et al. Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus: combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum 1988; 31: 623-31.
56. Senecal JL, Rauch J. Hybridoma lupus autoantibodies can bind major cytoskelet al. filaments in the absence of DNA-binding activity. Arthritis Rheum 1988; 31: 864-75.
57. Du L, Fukushima S, Sallmyr A, Manthorpe R, Bredberg A. Exposure of HEp-2 cells to stress conditions influences antinuclear antibody reactivity. Clin Diagn Lab Immunol 2002; 287-94. (Pubitemid 34226019)
58. Lu F, Kalman B. Autoreactive IgG to intracellular proteins in sera of MS patients. J Neuroimmunol 1999; 99: 72-81. (Pubitemid 29488571)
59. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lowdensity lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5. (Pubitemid 23109111)
60. Witzum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
61. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al.. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32. (Pubitemid 28397070)
62. Fujiwara N, Nakano M, Kato S, Yoshihara D, Ookawara T, Eguchi H, et al.. Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J Biol Chem 2007; 282: 35933-44. (Pubitemid 350277101)
63. D'Souza A, Kurien BT, Rodgers R, Shenoi J, Kurono S, Matsumoto H, et al.. Detection of catalase as a major protein target of the lipid peroxidation product 4-HNE and the lack of its genetic association as a risk factor in SLE. BMC Med Genet 2008; 9: 62.